Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
Mounjaro (tirzepatide) injection is a new dual-targeted therapy indicated for the management of type 2 diabetes in adults. The post Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA...
View ArticleRYTELO for the Treatment of Myelodysplastic Syndromes, US
RYTELO (imetelstat) is indicated for the treatment of low-to-intermediate-1-risk myelodysplastic syndromes (MDS) in adult patients who exhibit transfusion-dependent (TD) anaemia. The post RYTELO for...
View ArticleForxiga (dapagliflozin) for Treatment of Type 2 Diabetes
Forxiga® (dapagliflozin) is approved for the treatment of paediatric type 2 diabetes, chronic heart failure and chronic kidney disease. The post Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes...
View ArticleQALSODY (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis, Europe
Biogen's QALSODY (tofersen) is the first targeted therapy approved for a rare, genetic form of amyotrophic lateral sclerosis (ALS), SOD1-ALS. The post QALSODY (tofersen) for the Treatment of...
View ArticleEC conditionally approves Pfizer’s haemophilia B gene therapy
The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment. The post EC conditionally approves Pfizer’s haemophilia B gene therapy...
View ArticleELAHERE for the Treatment of Ovarian Cancer, US
ELAHERE® (mirvetuximab soravtansine) is a novel antibody-drug conjugate (ADC) indicated for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial...
View ArticleYunovia receives South Korea MFDS approval for Phase I trial of GLP-1 agonist
Yunovia has announced IND clearance from the MFDS of South Korea for a Phase I study of its glucagon-like peptide-1 agonist, ID110521156. The post Yunovia receives South Korea MFDS approval for Phase I...
View ArticleWegovy for the Treatment of Chronic Weight Management, US
Wegovy® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced diet and increased exercise for chronic weight management in overweight or generally...
View ArticleFRUZAQLA (fruquintinib) for the Treatment of Metastatic Colorectal Cancer, USA
FRUZAQLA® (fruquintinib) is an oral targeted therapy indicated for adult patients with metastatic colorectal cancer (mCRC). The post FRUZAQLA (fruquintinib) for the Treatment of Metastatic Colorectal...
View ArticleBALVERSA for the Treatment of Urothelial Carcinoma, US
BALVERSA® (erdafitinib) is a fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have...
View Article